EUCTR2007-002469-11-ES进行中（未招募）不适用
Estudio aleatorizado, doble ciego, de grupos paralelos, multicéntrico, para comparar la eficacia y seguridad de aliskiren 300 mg administrado una vez al día y de aliskiren 150 mg administrado dos veces al día en pacientes con hipertensión esencial
ovartis Farmaceutica S.A.0 个研究点目标入组 314 人开始时间: 2008年2月27日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 314
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female outpatients 18 years of age and older.
- •- Patients with a diagnosis of uncomplicated essential hypertension; newly
- •diagnosed or who have not received antihypertensive medication within 4 weeks of
- •Visit 1 must have an office cuff msDBP = 100 mmHg and = 110 mmHg at Visit 1.
- •- Patients receiving antihypertensive treatment must have a cuff msDBP of = 95 mmHg and = 110 mmHg at Visit 1.
- •- Prior to the randomization, all patients must have an office cuff msDBP = 100 mmHg and = 110 mmHg.
- •4. Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •For full list, see protocol
- •Patients with any of the following at Visit 1 or 2 at which the patient will be excluded from participation in the study.
- •1. Previously treated with aliskiren in the last six months or have previously participated in an aliskiren trial in this development program within the last six months and who qualified to be randomized or enrolled into the active drug treatment period.
- •2. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (= 5 mIU/ml).
- •3. Women of child-bearing potential (WOCBP), defined as all women physiologically
- •capable of becoming pregnant, including women whose career, lifestyle, or sexual
- •orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy OR are using one or more of the following acceptable methods of contraception: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception (implantable, patch, and oral), and double-barrier methods (if accepted by local ethics committee). Reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation.
- •4. Patients with an office cuff blood pressure of msDBP = 112 mmHg and/or msSBP = 200 mmHg
- •5. History or evidence of a secondary form of hypertension.
- •6. Previous or current diagnosis of heart failure (NYHA Class II, III and IV).
- •7. History of hypertensive encephalopathy or cerebrovascular accident, transient ischemic cerebral attack (TIA), myocardial infarction, coronary bypass surgery, or any
- •percutaneous coronary intervention (PCI).
- •8. Serum potassium = 5.3 mEq/L (mmol/L) at Visit 1.
- •9. Patients with Type 1 or Type 2 diabetes mellitus who are not well controlled as
- •determined by local country criteria. It is recommended that patients currently being
- •treated for diabetes mellitus be on a stable dose of antidiabetic medication for at least 4 weeks prior to Visit 1.
- •10. Current angina pectoris requiring pharmacological therapy (the use of nitrates for the treatment of angina will be allowed).
- •11. Second or third degree heart block without a pacemaker.
- •12. Potentially life threatening arrhythmia during the 12 months prior to Visit 1.
研究者
相似试验
进行中（未招募）
1 期
Estudio aleatorizado, doble ciego, de grupos paralelos, dosis fija, controlado con placebo, con duloxetina como fármaco de referencia, que evalúa la eficacia y seguridad de tres dosis de Lu AA21004 en el tratamiento agudo del trastorno depresivo mayor - No aplicaEUCTR2007-001870-95-ESH. Lundbeck A/S660
进行中（未招募）
1 期
Estudio aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, de Lu AE58054 a dosis fijas en pacientes con enfermedad de Alzheimer moderada tratados con donepeziloEnfermedad de AlzheimerMedDRA version: 9.1Level: LLTClassification code 10001896EUCTR2009-011845-24-ESH. Lundbeck A/S270
进行中（未招募）
1 期
Estudio aleatorizado, doble ciego, de grupos paralelos y dosis flexibles, controlado con un grupo activo, para evaluar la eficacia y la seguridad del tratamiento con Lu 31-130 durante 12 semanas en pacientes con esquizofrenia - N/Au 31-130 está en desarrollo por H. Lundbeck A/S como un antipsicótico en el tratamiento de la esquizofreniaMedDRA version: 9.1Level: PTClassification code 10039639Term: Schizophrenia, paranoid typeMedDRA version: 9.1Level: PTClassification code 10039637Term: Schizophrenia, catatonic typeMedDRA version: 9.1Level: PTClassification code 10039638Term: Schizophrenia, disorganised typeMedDRA version: 9.1Level: PTClassification code 10052792Term: Schizophrenia, undifferentiated typeEUCTR2008-000479-11-ESH. Lundbeck A/S120
进行中（未招募）
不适用
Estudio aleatorizado, doble ciego, de grupos paralelos, multicéntrico, controlado con placebo y fármaco activo en escalada de dosis para evaluar la eficacia y seguridad de LCZ696 de modo comparativo con valsartán, y para evaluar AHU377 respecto a placebo después de 8 semanas de tratamiento en pacientes con hipertensión esencialHipertension esencialMedDRA version: 9.1Level: LLTClassification code 10020775Term: Hypertension arterialEUCTR2007-001360-76-ESOVARTIS FARMACEUTICA S.A.1,560
进行中（未招募）
1 期
Estudio aleatorizado, doble ciego, de grupos paralelos de fase III de la eficacia y la seguridad de dabigatrán etexilato (150 mg bid) oral en comparación con warfarina (INR 2,0-3,0) para un tratamiento durante 6 meses de la tromboembolia venosa sintomática aguda después del tratamiento inicial durante al menos 5 días con un anticoagulante parenteral aprobado para esta indicación. RE-COVER IIA phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment for at least 5 days with a parenteral anticoagulant approved for this indication. RE-COVER II - RE-COVER IItromboembolia venosa sintomática agudaLa tromboembolia venosa se define como la incidencia compuesta de trombosis venosa profunda de la pierna (incluyendo la vena cava inferior) y embolia pulmonarAcute symptomatic VTEVTE is defined as the composite incidence of Deep Vein Thrombosis of the leg (including the inferior caval vein) and Pulmonary Embolism.MedDRA version: 9.1Level: LLTClassification code 10037377Term: Pulmonary embolismMedDRA version: 9.1Level: LLTClassification code 10047251Term: Venous thrombosis deep (limbs)EUCTR2007-002631-86-ESBoehringer Ingelheim España, S.A.2,550